What does Hikma Ventures invest in?
Hikma Ventures invests most often at Series A and Series C (57% of the rounds on record), in sectors such as Diagnostics, Celle Therapy and Healthier Living.

United Kingdom · Investor
Last cheque observed May 2023. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.
Corporate VCQuiet
Follow Hikma Ventures and see its new cheques in your feed. Start following
8 rounds on record
Mostly Series A and Series C: 57% of its rounds
Sole investor in 1 rounds, median undisclosed
We invest in businesses where our expertise and global presence can accelerate revenue growth, enhance value creation, and help differentiate Hikma's products.From their own website
Every round we can evidence, newest first8 appearances
1 round
2 rounds
2 rounds
1 round
1 round
1 round
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration15 named
We also hold 12 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From the firm's own filings with the UK company register, which it must file accurately by law
From their own portfolio page (on their website)
Activ SurgicalAltibbiAltoidaBiolinqClicktherapeuticsLemonaid -LightshipNebula Genomics -NuvoairOctavePillo -Propeller -SeamlessMDTactWinterlight -I2 TherapeuticsO7Prognos
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
The investors most often in the same rounds as Hikma Ventures. A count of rooms they were both in, not a relationship either has claimed.
The latest companies Hikma Ventures put money into.
Hikma Ventures invests most often at Series A and Series C (57% of the rounds on record), in sectors such as Diagnostics, Celle Therapy and Healthier Living.
8 investments on record, 0 of them in the last 12 months, and it led 1. The most recent was in May 2023.
Its most recent investments on record: Prognos Health (Growth, May 2023), Pillo Health (Series A, May 2019) and Biolinq (Series A, Mar 2019).
The median round it joins is $20M.
Sometimes: it led 1 of its 8 investments on record (13%).
Most of the companies it backs are in the United States (100%).
No investments in the last 12 months; the latest was in May 2023.
Most often Merck Global Health Innovation Fund (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it